The two vaccines used in South Africa’s vaccination programme, those from Johnson & Johnson and Pfizer/BioNTech, have both been shown to be highly effective against COVID-19, particularly in preventing hospitalisation and death. But protection may wane over time and new variants may or may not render these vaccines less effective. Adele Baleta unpacks what we do and do not know about the potential need for booster shots and surveys some of the studies that will help fill the gaps.
By 13 June official statistics from the Department of Health showed 382 255 people 60 years and older in the Eastern Cape registered for COVID-19 vaccination. So far, 114 661 of them received their first dose of the Pfizer vaccine. Luvuyo Mehlwana visited some rural areas to see how registration and vaccination are going.
South Africa is consolidating its place in the race for a COVID-19 vaccine with its participation starting from next month in two new international trials of vaccine candidates. Adele Baleta reports.